"The quality of the clinical data supporting the development
and ultimately the approval for medical use of new drugs is often
challenged. Many share the perception that the business goals of the
pharmaceutical industry overrule the best scientific efforts to accrue
critical knowledge on a new molecule, in order to inform investment of
resources, regulatory approvals and appropriate use by patients. Despite
this common belief, few scientists have attempted to assess objectively
the quality of industry funded (IF) clinical trials by measuring it and
comparing it with non-industry funded (NIF) clinical trials in a
data-driven fashion. Overall, the average quality of IF clinical
research has been reported to be higher than the quality of NIF clinical
research."
An ovarian cancer blog which includes quality resource materials: education, research, social networking, genetics and (some) healthcare politics.
“Not everything that can be counted counts and not everything that counts can be counted.”
Albert Einstein
No comments:
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.